If you look at the existing phase three trials, I think those were done at the expense of the vaccine producers.
As I said, it doesn't seem as though mixing and matching is necessarily in the financial interests of the vaccine companies. Who will provide the financing for those clinical trials to see whether this adds efficacy to the vaccines?